4//SEC Filing
Astle Christopher 4
Accession 0000950170-24-003087
CIK 0001937653other
Filed
Jan 7, 7:00 PM ET
Accepted
Jan 8, 6:14 PM ET
Size
15.7 KB
Accession
0000950170-24-003087
Insider Transaction Report
Form 4
Zymeworks Inc.ZYME
Astle Christopher
SVP & Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2024-01-05+10,500→ 12,497 total - Award
Restricted Stock Unit
2024-01-05+30,000→ 30,000 total→ Common Stock (30,000 underlying) - Exercise/Conversion
Restricted Stock Unit
2024-01-05−10,500→ 21,000 total→ Common Stock (10,500 underlying) - Award
Stock Option (Right to Buy)
2024-01-05+50,000→ 50,000 totalExercise: $10.56Exp: 2034-01-04→ Common Stock (50,000 underlying) - Sale
Common Stock
2024-01-08$11.22/sh−1,431$16,050→ 6,503 total - Sale
Common Stock
2024-01-05$10.65/sh−4,563$48,606→ 7,934 total
Footnotes (8)
- [F1]Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 5, 2023.
- [F2]Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.55 to $10.845, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F4]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.49 to $11.58, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F5]Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
- [F6]The RSUS were granted on January 5, 2023 and vest in three equal annual installments beginning on January 5, 2024.
- [F7]Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date.
- [F8]The RSUs vest in three equal annual installments beginning on January 5, 2025.
Documents
Issuer
Zymeworks Inc.
CIK 0001937653
Entity typeother
Related Parties
1- filerCIK 0001915257
Filing Metadata
- Form type
- 4
- Filed
- Jan 7, 7:00 PM ET
- Accepted
- Jan 8, 6:14 PM ET
- Size
- 15.7 KB